Featured Press Releases

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

Moleculin

Moleculin's AML treatment gets EMA's Orphan Drug Designation

  • 18 Apr 2024

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage...

UPSHER-SMITH LAUNCHES METHIMAZOLE TABLETS, USP

UPSHER-SMITH LAUNCHES METHIMAZOLE TABLETS, USP

The American Kidney Fund

The American Kidney Fund's Rare Kidney Disease Advocacy Day on Capitol Hill aims to gather support for legislation to boost awareness and treatment of rare kidney diseases.

Solu Therapeutics appoints Sergio Santillana, MD, as Chief Medical Officer to strengthen its leadership team.

Solu Therapeutics appoints Sergio Santillana, MD, as Chief Medical Officer to strengthen its leadership team.

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

  • Novaliq
  • 09 Jul 2025
Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

  • DualityBio
  • 08 Jul 2025
With Fifth NovaSeq X Plus System in Europe, Novogene Europe Expands Sequencing Capabilities

With Fifth NovaSeq X Plus System in Europe, Novogene Europe Expands Sequencing Capabilities

  • Novogene
  • 07 Jul 2025
Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

  • AudioCure
  • 07 Jul 2025
The European Commission grants Aurobindo Pharma approval to market the cancer drug, Dazublys

The European Commission grants Aurobindo Pharma approval to market the cancer drug, Dazublys

  • Aurobindo Pharma
  • 02 Jul 2025
Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

  • Fresenius Kabi
  • 01 Jul 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
July   2025
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31      

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.